Investors largely expected the FOMC to cut rates by a quarter point.The Fedread more
The interest on excess reserves now stands at 1.8%, a 30 basis point cut compared to the 25 basis point reduction for the benchmark funds rate.The Fedread more
The decision to cut rates followed a monthslong pressure campaign by Trump, who often criticized Chairman Jerome Powell by name as he called for lower interest rates.Politicsread more
This is a comparison of Wednesday's FOMC statement with the one issued on July 31 after the Fed's previous policymaking meeting.The Fedread more
Ahead of the Fed's 2 p.m. announcement, many economists were forecasting one further cut in 2019, but some investors were hoping for two more this year.The Fedread more
The Fed has become increasingly divided with three officials voting against the Fed's quarter point cut to the fed funds target rate range.Market Insiderread more
Stocks traded lower on Wednesday as traders digested the Federal Reserve's latest decision on U.S. monetary policy.US Marketsread more
For consumers, lower rates do mean cheaper loans, which can impact your mortgage, home equity loan, credit card, student loan tab and car payment. n the flip side, you'll earn...Personal Financeread more
Gold edged lower on Wednesday but held about the key $1,500 per ounce level after the U.S. Federal Reserve decided to cut interest rates.Futures & Commoditiesread more
As the Federal Reserve lowers rates, some banks are pulling back their offerings on their savings accounts and certificates of deposit. Even so, they are still pretty good by...Personal Financeread more
SAN ANTONIO, July 07, 2016 (GLOBE NEWSWIRE) -- bioAffinity Technologies today announced that William Bauta, Ph.D., will join the company in September 2016 as Senior Vice President for Research and Development, Therapeutics. Dr. Bauta will direct the development and commercialization of targeted drugs for the treatment of multiple cancers at bioAffinity’s wholly owned subsidiary, OncoSelect Therapeutics, LLC.
“Dr. Bauta’s 25 years of experience in the discovery, development and commercialization of pharmaceuticals for oncology and a wide array of life-threatening diseases will shorten the timeframe to adapt our proprietary porphyrin-based technology to the targeted cancer therapeutics market,” said bioAffinity President and CEO Maria Zannes. “His expertise in the field of medicinal chemistry complements and builds upon the extraordinary caliber of our scientific team under the direction of Dr. Vivienne Rebel.”
Dr. Bauta is currently the manager for medicinal and process chemistry at Southwest Research Institute where he helped develop its pharmaceuticals services and bioengineering business. Previously, he was Associate Director of science at Genzyme Corporation and held a similar position at Ilex Products, Inc., where he was responsible for the discovery, development and FDA approval of multiple therapeutics. He holds several patents and has published in more than a dozen scientific journals, including the journal Science. Dr. Bauta received his Ph.D. from the University of Chicago where he received fellowships from the National Science Foundation and the American Chemical Society. His post-doctoral studies were at the University of Texas at Austin under a National Institutes of Health fellowship.
bioAffinity’s porphyrin-based CyPath® bio-label preferentially binds to cancer cells, giving them a distinctive fluorescence detectable by an imaging system. OncoSelect will take advantage of CyPath®’s unique characteristics to deliver targeted porphyrin therapeutics that will be available to partners through a variety of licensing agreements.
About bioAffinity Technologies
bioAffinity Technologies, Inc. (www.bioaffinitytech.com) is a privately held development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The Company develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. Research and optimization of its platform technology is conducted in bioAffinity Technologies’ laboratories and at the University of Texas Health Science Center at San Antonio through a collaborative research agreement. The Company’s platform technology will be developed to diagnose, monitor, and treat many cancers. CyPath® Lung, bioAffinity’s initial product, is designed to be the first successful non-invasive, early-stage lung cancer diagnostic on the market.
Contact: Maria Zannes, 505.400.9747
Source: bioAffinityTechnologies, Inc.